Skip to main content
Premium Trial:

Request an Annual Quote

Princeton Licenses Oncology Genes to Genome Therapeutics

Premium

WALTHAM, Mass.--Genome Therapeutics here announced that it acquired an exclusive license to proprietary genes regulated by the T53 tumor suppressor gene from Prince ton University. The agreement will enable Genome Therapeutics to develop proprietary targets within the p53 signal pathway that could lead to the identification of potential gene therapies and the development of new cancer treatments. Under terms of the agreement, Princeton will receive an undisclosed license fee and share in any product royalties created through future alliances.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.